959983-22-3

Upstream product

• 928843-71-4 (1aR,12bS)-8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid 
• 902148-54-3 13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6-carboxylic acid methyl ester 
• 1033906-14-7 (+/-)-8-cyclohexyl-11-(methyloxy)-1a-((methyloxy)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxylic acid 
• 879498-90-5 1H-indole-6-carboxylic acid, 2-bromo-3-cyclohexyl-, 1,1-dimethylethyl ester 
• 928844-30-8 13-cyclohexyl-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid 10-(1,1-dimethylethyl) ester 6-methyl ester 
• 108-94-1 cyclohexanone 
• 902148-40-7 2-bromo-3-cyclohexyl-N-[(dimethylamino)sulfonyl]-1H-indole-6-carboxamide 
• 958002-14-7 6H-Isoindolo[2,1-a]indole-3-carboxamide, 11-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-ethoxy-8-methoxy- 
• 928844-26-2 3-cyclohexyl-N-[(dimethylamino)sulfonyl]-2-(2-formyl-4-methoxyphenyl)-1H-indole-6-carboxamide 
• 902148-53-2 11-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-hydroxy-8-methoxy-6H-isoindolo[2,1-a]indole-3-carboxamide 
• 50820-65-0 indole-6-carboxylic acid methyl ester 
• 1670-82-2 Indole-6-carboxylic acid 
• 494799-76-7 2-bromo-3-cyclohexyl-1H-indole-6-carboxylic acid 
• 494799-19-8 methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate 

Downstream Products

• 1059609-01-6 rac-8-cyclohexyl-N-((dimethylamino)sulfonyl)-1a-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-ylcarbonyl)-11-methoxy-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 1059608-90-0 C₃₆H₄₅N₅O₅S 
• 928844-29-5 (1aS,12bR)-8-cyclohexyl-N⁵-[(dimethylamino)sulfonyl]-1,12b-dihydro-N^1a-[(2R,3S)-3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-11-methoxy-cycloprop[d]indolo[2,1-a][2]benzazepine-1a,5(2H)-dicarboxamide 
• 928844-28-4 (1aR,12bS)-8-cyclohexyl-N⁵-[(dimethylamino)sulfonyl]-1,12b-dihydro-N^1a-[(2R,3S)-3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-11-methoxy-cycloprop[d]indolo[2,1-a][2]benzazepine-1a,5(2H)-dicarboxamide 
• 1058165-55-1 8-cyclohexyl-N-((dimethylamino)sulfonyl)-11-methoxy-1a-((3-(1-piperidinyl)-8-azabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 1058130-37-2 8-Cyclohexyl-N-((dimethylamino)sulfonyl)-11-methoxy-1a-((2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 1058130-62-3 8-Cyclohexyl-N₅-(dimethylsulfamoyl)-11-methoxy-N₁a-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepine-1a,5(2H)-dicarboxamide 
• 1058130-66-7 C₃₉H₄₅N₅O₅S 
• 1058130-49-6 8-cyclohexyl-N₁a-((1R,2R)-2-(dimethylamino)cyclopentyl)-N₅-((dimethylamino)sulfonyl)-11-methoxy-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepine-1a,5(2H)-dicarboxamide 
• 1058130-40-7 8-cyclohexyl-N₅-((dimethylamino)sulfonyl)-11-methoxy-N₁a-methyl-N₁a-((1-methyl-2-pyrrolidinyl)methyl)-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepine-1a,5(2H)-dicarboxamide 
• 1058130-41-8 8-cyclohexyl-N₅-((dimethylamino)sulfonyl)-11-methoxy-N₁a-methyl-N₁a-((1-methyl-2-piperidinyl)methyl)-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepine-1a,5(2H)-dicarboxamide 
• 1058130-47-4 8-cyclohexyl-N₁a-(2-(dimethylamino)-1-phenylethyl)-N₅-((dimethylamino)sulfonyl)-11-methoxy-N₁a-methyl-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepine-1a,5(2H)-dicarboxamide 
• 1058130-60-1 cycloprop[d]indolo[2,1-a][2]benzazepine-1a,5(2H)-dicarboxamide, 8-cyclohexyl-N₅-[(dimethylamino)sulfonyl]-1,12b-dihydro-11-methoxy-N₁a-methyl-N₁a-(7-methyl-7-azabicyclo[2.2.1]hept-2-yl)- 

Relevant academic research and scientific papers

Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS

The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.